Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction.

PubWeight™: 0.88‹?›

🔗 View Article (PMC 1576185)

Published in Br J Pharmacol on July 01, 2005

Authors

Melinda Wuest1, Juliane Hecht, Torsten Christ, Manfred Braeter, Christian Schoeberl, Oliver W Hakenberg, Manfred P Wirth, Ursula Ravens

Author Affiliations

1: Institute of Pharmacology and Toxicology, Dresden University of Technology, Fetscherstrasse 74, D-01307 Dresden, Germany. melinda.wuest@mailbox.tu-dresden.de

Articles citing this

Actions of two main metabolites of propiverine (M-1 and M-2) on voltage-dependent L-type Ca2+ currents and Ca2+ transients in murine urinary bladder myocytes. J Pharmacol Exp Ther (2007) 0.88

Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction. Naunyn Schmiedebergs Arch Pharmacol (2006) 0.85

Functional investigation of β-adrenoceptors in human isolated detrusor focusing on the novel selective β3-adrenoceptor agonist KUC-7322. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.83

Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites? Naunyn Schmiedebergs Arch Pharmacol (2006) 0.83

Anticholinergic effects of cis- and trans-isomers of two metabolites of propiverine. Naunyn Schmiedebergs Arch Pharmacol (2010) 0.81

Electrophysiological profile of propiverine--relationship to cardiac risk. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.81

Age-dependent contribution of Rho kinase in carbachol-induced contraction of human detrusor smooth muscle in vitro. Acta Pharmacol Sin (2013) 0.80

The muscarinic receptor antagonist propiverine exhibits α(1)-adrenoceptor antagonism in human prostate and porcine trigonum. World J Urol (2011) 0.79

Effect of rilmakalim on detrusor contraction in the presence and absence of urothelium. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.78

Efficacy of propiverine ER with or without α-blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional study. World J Urol (2011) 0.78

Oral absorption of propiverine solution and of the immediate and extended release dosage forms: influence of regioselective intestinal elimination. Eur J Clin Pharmacol (2008) 0.75

Muscarinic receptor expression and receptor-mediated detrusor contraction: comparison of juvenile and adult porcine tissue. Pflugers Arch (2007) 0.75

Articles cited by this

Some quantitative uses of drug antagonists. Br J Pharmacol Chemother (1959) 41.90

Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev (1993) 2.87

Management of overactive bladder. N Engl J Med (2004) 2.52

A comparison of spontaneous and nerve-mediated activity in bladder muscle from man, pig and rabbit. J Physiol (1984) 2.30

Antimuscarinics and the overactive detrusor--which is the main mechanism of action? Eur Urol (2003) 1.50

Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther (2004) 1.29

An essential role of Cav1.2 L-type calcium channel for urinary bladder function. FASEB J (2004) 1.26

The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol (2002) 1.23

A quantitative study of atropine-resistant contractile responses in human detrusor smooth muscle, from stable, unstable and obstructed bladders. J Urol (1999) 1.19

Signal transduction underlying carbachol-induced contraction of rat urinary bladder. I. Phospholipases and Ca2+ sources. J Pharmacol Exp Ther (2003) 1.11

Which muscarinic receptor is important in the bladder? World J Urol (2001) 1.06

The role of M(2)-muscarinic receptors in mediating contraction of the pig urinary bladder in vitro. Br J Pharmacol (2000) 1.06

The pharmacological treatment of urinary incontinence. BJU Int (1999) 1.06

M(3) muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol (2002) 1.05

Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol (2001) 1.01

Pharmacological characterization of muscarinic receptors in mouse isolated urinary bladder smooth muscle. Br J Pharmacol (2001) 0.99

Ca(2+) channel properties in smooth muscle cells of the urinary bladder from pig and human. Eur J Pharmacol (2002) 0.98

Cholinergic and purinergic responses in isolated human detrusor in relation to age. J Urol (2005) 0.94

Comparison of the effects of various anticholinergic drugs on human isolated urinary bladder. Arch Int Pharmacodyn Ther (1996) 0.89

Inhibitory effects of propiverine on rat and guinea-pig urinary bladder muscle. Naunyn Schmiedebergs Arch Pharmacol (1993) 0.85

Pharmacological effects of tolterodine on human isolated urinary bladder. Eur J Pharmacol (1999) 0.84

On the pharmacokinetics and metabolism of propiverine in man. Eur J Drug Metab Pharmacokinet (1989) 0.81

Anticholinergic properties of propiverine and its metabolites. Pharmazie (1990) 0.80

Potential therapeutic targets for treatment of the overactive bladder. World J Urol (2001) 0.80

[Effects of propiverine hydrochloride and its metabolites on isolated guinea pig urinary bladder]. Nihon Yakurigaku Zasshi (1989) 0.79

Pharmacokinetics and safety of propiverine in patients with fatty liver disease. Eur J Clin Pharmacol (1999) 0.79

Different responses to drugs against overactive bladder in detrusor muscle of pig, guinea pig and mouse. Eur J Pharmacol (2002) 0.78

Mechanical response to electrical field stimulation of rat, guinea-pig, monkey and human detrusor muscle: a comparative study. Naunyn Schmiedebergs Arch Pharmacol (2001) 0.78

Articles by these authors

Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet (2012) 5.00

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int (2006) 3.39

Assessing the impact of ischaemia time during partial nephrectomy. Eur Urol (2009) 3.18

A new approach to transcription factor screening for reprogramming of fibroblasts to cardiomyocyte-like cells. J Mol Cell Cardiol (2012) 2.71

Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circulation (2012) 2.58

The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace (2009) 2.52

Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. Circ Arrhythm Electrophysiol (2008) 2.37

Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation (2005) 2.15

Assessing the accuracy and generalizability of the preoperative and postoperative Karakiewicz nomograms for renal cell carcinoma: results from a multicentre European and US study. BJU Int (2013) 2.08

Laparoscopic living-donor nephrectomy: analysis of the existing literature. Eur Urol (2010) 2.07

Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol (2002) 2.02

Second cancers as competing causes of death after radical prostatectomy. J Urol (2009) 2.02

Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation. Circulation (2006) 2.00

Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J (2007) 1.90

Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin Cancer Res (2003) 1.83

Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation (2004) 1.77

Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate (2006) 1.74

Advances in specific immunotherapy for prostate cancer. Eur Urol (2007) 1.70

Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project). Eur Urol (2012) 1.69

Human atrial ion channel and transporter subunit gene-expression remodeling associated with valvular heart disease and atrial fibrillation. Circulation (2005) 1.67

Functional modulation of the transient outward current Ito by KCNE beta-subunits and regional distribution in human non-failing and failing hearts. Cardiovasc Res (2006) 1.62

Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma--results from a comprehensive multi-centre database (CORONA/SATURN-Project). BJU Int (2013) 1.60

Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ Res (2009) 1.58

Prevention and management of complications following radical cystectomy for bladder cancer. Eur Urol (2010) 1.57

Incidence, prevention, and management of complications following percutaneous nephrolitholapaxy. Eur Urol (2011) 1.55

Decreased ATP-sensitive K(+) current density during chronic human atrial fibrillation. J Mol Cell Cardiol (2003) 1.54

Electrophysiological properties of human mesenchymal stem cells. J Physiol (2003) 1.53

Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol (2011) 1.49

Left-to-right atrial inward rectifier potassium current gradients in patients with paroxysmal versus chronic atrial fibrillation. Circ Arrhythm Electrophysiol (2010) 1.49

Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace (2007) 1.46

Evaluation of dose-volume histograms after prostate seed implantation. 4-year experience. Strahlenther Onkol (2004) 1.44

Expression and function of dipeptidyl-aminopeptidase-like protein 6 as a putative beta-subunit of human cardiac transient outward current encoded by Kv4.3. J Physiol (2005) 1.43

Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases. Can J Urol (2012) 1.43

An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol (2009) 1.42

Expression of Ki-67 in squamous cell carcinoma of the penis. BJU Int (2005) 1.39

Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643). Mol Pharmacol (2005) 1.37

Quantitative multi-gene expression profiling of primary prostate cancer. Prostate (2006) 1.36

Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace (2011) 1.35

Perioperative complications of radical cystectomy in a contemporary series. Eur Urol (2006) 1.35

External validation of a model to predict locoregional failure after radical cystectomy. Cancer (2014) 1.34

Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array. Neoplasia (2008) 1.32

Adult zebrafish heart as a model for human heart? An electrophysiological study. J Mol Cell Cardiol (2009) 1.29

Comparison of the American Society of Anesthesiologists Physical Status classification with the Charlson score as predictors of survival after radical prostatectomy. Urology (2003) 1.29

Epinephrine activates both Gs and Gi pathways, but norepinephrine activates only the Gs pathway through human beta2-adrenoceptors overexpressed in mouse heart. Mol Pharmacol (2004) 1.21

Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 1.21

Update of the guidelines on sudden cardiac death of the European Society of Cardiology. Eur Heart J (2003) 1.21

Remodeling of cardiomyocyte ion channels in human atrial fibrillation. Basic Res Cardiol (2003) 1.20

Transmural expression of ion channels and transporters in human nondiseased and end-stage failing hearts. Pflugers Arch (2009) 1.20

Lymphadenectomy in the surgical management of penile cancer. Eur Urol (2009) 1.19

Ionic mechanisms limiting cardiac repolarization reserve in humans compared to dogs. J Physiol (2013) 1.17

Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace (2013) 1.16

Human inward rectifier potassium channels in chronic and postoperative atrial fibrillation. Cardiovasc Res (2002) 1.15

Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int (2010) 1.13

Elevated expression of prostate cancer-associated genes is linked to down-regulation of microRNAs. BMC Cancer (2014) 1.12

Distinct contractile and molecular differences between two goat models of atrial dysfunction: AV block-induced atrial dilatation and atrial fibrillation. J Mol Cell Cardiol (2008) 1.09

What really matters is rarely measured: outcome of routine care and patient-reported outcomes. Eur Urol (2013) 1.09

Charlson score and competing mortality. Cancer (2014) 1.09

Comorbidity and mortality after brachytherapy: in regard to Nanda et al. Int J Radiat Oncol Biol Phys (2013) 1.07

Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient. Int J Cancer (2009) 1.07

Re: Robot-assisted versus open radical prostatectomy: the differential effect of regionalization, procedure volume and operative approach: J. D. Sammon, P. I. Karakiewicz, M. Sun, S. Sukumar, P. Ravi, K. R. Ghani, M. Bianchi, J. O. Peabody, S. F. Shariat, P. Perrotte, J. C. Hu, M. Menon and Q. D. Trinh J Urol 2013; 189: 1289-1294. J Urol (2013) 1.07

Socio-economic deprivation and cancer survival in Germany. Int J Cancer (2014) 1.07

Re: Roman Mayr, Matthias May, Thomas Martini, et al. Comorbidity and performance indices as predictors of cancer-independent mortality but not of cancer-specific mortality after radical cystectomy for urothelial carcinoma of the bladder. Eur Urol 2012;62:662-70. Eur Urol (2012) 1.07

Specific beta(2)AR blocker ICI 118,551 actively decreases contraction through a G(i)-coupled form of the beta(2)AR in myocytes from failing human heart. Circulation (2002) 1.07

Differential phosphorylation-dependent regulation of constitutively active and muscarinic receptor-activated IK,ACh channels in patients with chronic atrial fibrillation. Cardiovasc Res (2007) 1.06

Effect of age, tumor risk, and comorbidity in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med (2013) 1.06

Cardiac mechano-electric feedback: past, present, and prospect. Prog Biophys Mol Biol (2003) 1.06

Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma. BJU Int (2006) 1.06

Re: Vincenzo Ficarra, Giacomo Novara, Raymond C. Rosen, et al. systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol 2012;62:405-17. Eur Urol (2012) 1.06

Outcome of surgical treatment of isolated local recurrence after radical nephrectomy for renal cell carcinoma. J Urol (2002) 1.05

Dendritic cell-based immunotherapy for prostate cancer. Clin Dev Immunol (2010) 1.05

Comparing the global mRNA expression profile of human atrial and ventricular myocardium with high-density oligonucleotide arrays. J Thorac Cardiovasc Surg (2005) 1.05

Multiple potential molecular contributors to atrial hypocontractility caused by atrial tachycardia remodeling in dogs. Circ Arrhythm Electrophysiol (2010) 1.05

siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol (2004) 1.03

Inotropy and L-type Ca2+ current, activated by beta1- and beta2-adrenoceptors, are differently controlled by phosphodiesterases 3 and 4 in rat heart. Br J Pharmacol (2009) 1.02

Changes in I K, ACh single-channel activity with atrial tachycardia remodelling in canine atrial cardiomyocytes. Cardiovasc Res (2007) 1.01

Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. Europace (2009) 1.01

Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR. Int J Oncol (2003) 1.01

Biophysical characterization of the new human ether-a-go-go-related gene channel opener NS3623 [N-(4-bromo-2-(1H-tetrazol-5-yl)-phenyl)-N'-(3'-trifluoromethylphenyl)urea]. Mol Pharmacol (2006) 1.01

Which patients are at the highest risk of dying from competing causes ≤ 10 years after radical prostatectomy? BJU Int (2011) 1.00

Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. Eur Heart J (2009) 1.00

Isolation and enrichment of urologic tumor cells in blood samples by a semi-automated CD45 depletion autoMACS protocol. Int J Oncol (2002) 0.99

Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer (2002) 0.98

Molecular and functional expression of voltage-operated calcium channels during osteogenic differentiation of human mesenchymal stem cells. J Bone Miner Res (2005) 0.98

Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma. PLoS One (2013) 0.97

Contribution of Ca2+ influx to carbachol-induced detrusor contraction is different in human urinary bladder compared to pig and mouse. Eur J Pharmacol (2007) 0.96